These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 31628417)
1. The complement cascade in Alzheimer's disease: a systematic review and meta-analysis. Krance SH; Wu CY; Zou Y; Mao H; Toufighi S; He X; Pakosh M; Swardfager W Mol Psychiatry; 2021 Oct; 26(10):5532-5541. PubMed ID: 31628417 [TBL] [Abstract][Full Text] [Related]
2. Endosomal-Lysosomal and Autophagy Pathway in Alzheimer's Disease: A Systematic Review and Meta-Analysis. Krance SH; Wu CY; Chan ACY; Kwong S; Song BX; Xiong LY; Ouk M; Chen MH; Zhang J; Yung A; Stanley M; Herrmann N; Lanctôt KL; Swardfager W J Alzheimers Dis; 2022; 88(4):1279-1292. PubMed ID: 35754279 [TBL] [Abstract][Full Text] [Related]
3. Neutrophil activation in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid. Wu CY; Bawa KK; Ouk M; Leung N; Yu D; Lanctôt KL; Herrmann N; Pakosh M; Swardfager W Ageing Res Rev; 2020 Sep; 62():101130. PubMed ID: 32712109 [TBL] [Abstract][Full Text] [Related]
4. Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression. Zinellu A; Mangoni AA Front Immunol; 2021; 12():696085. PubMed ID: 34163491 [TBL] [Abstract][Full Text] [Related]
5. CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab. Sandoval C; Lee J; Toth B; Nagaraj R; Schauer SP; Hoffman J; Calderon E; Kollmorgen G; Sanabria Bohórquez SM; Monteiro C; Teng E; Hanson JE; Yeh FL; Gutierrez J; Biever A Alzheimers Dement; 2024 Oct; ():. PubMed ID: 39369294 [TBL] [Abstract][Full Text] [Related]
6. Impact of Preanalytical Procedures on Complement Biomarkers in Cerebrospinal Fluid and Plasma from Controls and Alzheimer's Disease Patients. Gutierrez J; Kurz C; Sandoval C; Edmonds R; Bittner T; Perneczky R; Biever A J Alzheimers Dis; 2024; 101(2):563-576. PubMed ID: 39213066 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. Daborg J; Andreasson U; Pekna M; Lautner R; Hanse E; Minthon L; Blennow K; Hansson O; Zetterberg H J Neural Transm (Vienna); 2012 Jul; 119(7):789-97. PubMed ID: 22488444 [TBL] [Abstract][Full Text] [Related]
8. The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer's Disease. Morgan AR; Touchard S; O'Hagan C; Sims R; Majounie E; Escott-Price V; Jones L; Williams J; Morgan BP J Alzheimers Dis; 2017; 56(1):25-36. PubMed ID: 27911318 [TBL] [Abstract][Full Text] [Related]
9. Expression of complement system components during aging and amyloid deposition in APP transgenic mice. Reichwald J; Danner S; Wiederhold KH; Staufenbiel M J Neuroinflammation; 2009 Nov; 6():35. PubMed ID: 19917141 [TBL] [Abstract][Full Text] [Related]
10. Plasma Clusterin as a Potential Biomarker for Alzheimer's Disease-A Systematic Review and Meta-analysis. Shi X; Xie B; Xing Y; Tang Y Curr Alzheimer Res; 2019; 16(11):1018-1027. PubMed ID: 31647395 [TBL] [Abstract][Full Text] [Related]
11. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. Zhou J; Fonseca MI; Pisalyaput K; Tenner AJ J Neurochem; 2008 Sep; 106(5):2080-92. PubMed ID: 18624920 [TBL] [Abstract][Full Text] [Related]
12. Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Veerhuis R; van der Valk P; Janssen I; Zhan SS; Van Nostrand WE; Eikelenboom P Virchows Arch; 1995; 426(6):603-10. PubMed ID: 7655742 [TBL] [Abstract][Full Text] [Related]
13. Early complement components in Alzheimer's disease brains. Veerhuis R; Janssen I; Hack CE; Eikelenboom P Acta Neuropathol; 1996; 91(1):53-60. PubMed ID: 8773146 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis. Chen Z; Liu C; Zhang J; Relkin N; Xing Y; Li Y Fluids Barriers CNS; 2017 May; 14(1):13. PubMed ID: 28486988 [TBL] [Abstract][Full Text] [Related]
15. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. Emmerling MR; Spiegel K; Watson MD Immunopharmacology; 1997 Dec; 38(1-2):101-9. PubMed ID: 9476121 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values. Mulder SD; Hack CE; van der Flier WM; Scheltens P; Blankenstein MA; Veerhuis R J Alzheimers Dis; 2010; 22(4):1073-9. PubMed ID: 20930309 [TBL] [Abstract][Full Text] [Related]
17. CSF markers related to pathogenetic mechanisms in Alzheimer's disease. Mulder C; Schoonenboom SN; Wahlund LO; Scheltens P; van Kamp GJ; Veerhuis R; Hack CE; Blomberg M; Schutgens RB; Eikelenboom P J Neural Transm (Vienna); 2002 Dec; 109(12):1491-8. PubMed ID: 12486489 [TBL] [Abstract][Full Text] [Related]
18. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213 [TBL] [Abstract][Full Text] [Related]
19. Activation of complement and contact system in Alzheimer's disease. Bergamaschini L; Donarini C; Gobbo G; Parnetti L; Gallai V Mech Ageing Dev; 2001 Nov; 122(16):1971-83. PubMed ID: 11589915 [TBL] [Abstract][Full Text] [Related]
20. Complement activation by C-reactive protein on the HEp-2 cell substrate. Vaith P; Prasauskas V; Potempa LA; Peter HH Int Arch Allergy Immunol; 1996 Oct; 111(2):107-17. PubMed ID: 8859218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]